Fri, 21st May 2021 21:18
May 21 (Reuters) - AstraZeneca's COVID-19 vaccine
was only slightly less effective against the variant first found
in India than the strain identified in Kent, the company's Chief
Executive Officer Pascal Soriot said in an interview with
Financial Times on Friday.
He added the company is in talks with governments, including
the United Kingdom, about new contracts for booster doses.
(Reporting by Radhika Anilkumar in Bengaluru; Editing by Chris
Reese)
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:
(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump...
(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth readi...
(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover ta...
Q1 revenue up 19% to $12.68 bln *
Astrazeneca (AZN)